Edwards Lifesciences is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, we collaborate with the world’s leading clinicians and researchers to address unmet healthcare needs, working to improve outcomes and enhance lives.
Since our establishment as an independent public company in 2000, Edwards has grown to more than $3.8 billion in revenue with product sales in more than 100 countries. We drive the development of minimally invasive technologies that improve both patient outcomes and speed of recovery. Our medical technologies include transcatheter and surgical heart valve therapies and critical care technologies:
Every year, Edwards Lifesciences creates new products with the power to save lives. In 2018, Edwards Lifesciences received several product approvals for commercialization:
Edwards has continued our focus on innovation. Please see our Newsroom for updates on our latest innovations and approvals.
Also in 2018, we entered into an accelerated share repurchase agreement to acquire $400 million of Edwards' common stock. Upon entering into the agreement, Edwards received 2.5 million shares.
Edwards is incorporated in Delaware and headquartered in Irvine, California, USA. We operate major manufacturing facilities in the United States, Puerto Rico, the Dominican Republic, Costa Rica and Singapore. We also have a significant employee presence at regional locations in Europe, Canada and Japan, with an office in Ireland where a manufacturing facility is under construction, expected to open in 2021 and employ approximately 600 people. None of our North American employees are represented by a labor union. In various countries outside of North America, we interact with trade unions and work councils that represent a limited number of employees.
|Total Number of Operations||65 (7 manufacturing locations)|
|Total Number of Employees as of December 31, 2018
(Including Part-Time and Temporary Employees)
|Global Employees by Gender in 2018||61% Female
Note: In 2018, we announced the planned construction of a new manufacturing facility in Ireland expected to be complete in 2021.
Across the U.S. and international markets, our customers include physicians, medical professionals, hospitals and group purchasing organizations. In 2018, we derived 55 percent of our sales from the U.S. and 45 percent from international markets.
Our primary direct materials suppliers provide:
We source about 80 percent of our manufacturing materials spend from preferred and strategic suppliers. We control the addition of new suppliers, which we add only if new technology or capability is required for our business and not already present in our supplier base. In recent years, we added around five to eight new direct materials suppliers per year. Newly added suppliers undergo a thorough due diligence process including screening for adverse conditions or events. We prioritize partnerships with suppliers headquartered in countries that enforce stringent standards and regulations to help reduce risks of non-compliance in our supply chain. For example, we source bovine pericardial tissue exclusively from the U.S. and Australia. Our largest indirect suppliers provide telecommunication services, food and catering services, office supplies, uniforms, lab products and cloud software.
We use Governance Maps to show the process used to establish accountability for each material topic in one overarching, interactive graphic. Our maps illustrate Edwards’ internal responsibility structures for managing our material topics. Each section describes who is involved when we set, execute and communicate our strategy. In 2018, we added two new topics to the map: Supply Chain Management and Talent Management.